B. Cosio (Palma De Mallorca, Spain), R. Rodríguez-Roisin (Barcelona, Spain), M. Corradi (Parma, Italy), R. Dahl (Aarhus, Denmark)
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
M. Decramer, B. Celli, N. Metzdorf, I. Leimer, D. Tashkin (Leuven, Belgium; Boston, Los Angeles, United States Of America; Ingelheim, Germany)
|  |
Poor generalisability of uplift findings to clinical practice
S. Walker, J. Fingleton, M. Weatherall, R. Beasley (Wellington, New Zealand)
|  |
Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1&2 COPD
J. Porszasz, S. Ma, R. Cao, A. Gore, W. Phillips, R. Cooper, F. Maltais, G. T. Ferguson, D. E. O'Donnell, H. Paden, R. Casaburi (Torrance, Urbana, Livonia, Ridgefield, United States Of America; Québec, Kingston, Canada)
| |
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
R. Wise, A. Anzueto, P. Calverley, R. Dahl, D. Dusser, G. Pledger, M. Koenen-Bergmann, E. Joseph, D. Cotton, B. Disse (Baltimore, San Antonio, Hamilton, Ridgefield, United States Of America; Liverpool, United Kingdom; Aarhus, Denmark; Paris, France; Ingelheim, Germany)
| |
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol
C. Vogelmeier, L. Fabbri, T. Glaab, D. Wyszynski, I. Leimer, N. Metzdorf, K. M. Beeh, K. Rabe (Marburg, Ingelheim, Wiesbaden, Großhansdorf, Germany; Modena, Italy; Bracknell, United Kingdom)
| |
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol
K. M. Beeh, K. Rabe, T. Glaab, D. Wyszynski, I. Leimer, N. Metzdorf, C. Vogelmeier, L. Fabbri (Wiesbaden, Großhansdorf, Ingelheim, Marburg, Germany; Bracknell, United Kingdom; Modena, Italy)
| |
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
D. Banerji, A. FowlerTaylor, P. Kho, H. Chen, V. Alagappan (East Hanover, United States Of America)
| |
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
M. Decramer, J. A. Wedzicha, J. H. Ficker, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Leuven, Belgium; London, United Kingdom; Nuernberg, Germany; East Hanover, United States Of America)
| |
Once-daily QVA149 has a good safety profile in patients with COPD
T. Welte, C. Vogelmeier, R. Dahl, K. R. Chapman, M. Rudolf, R. Mehta, P. D'Andrea, H. Chen, D. Banerji (Hanover, Marburg, Germany; Aarhus, Denmark; Toronto, Canada; Middlesex, United Kingdom; Indore, India; East Hanover, United States Of America)
| |
Once-daily indacaterol 150µg or 300µg and other bronchodilators in COPD patients of GOLD 2011 groups A and B
H. Kerstjens, O. Kornmann, G. Deslée, D. Young, D. Lawrence, D. McBryan (Groningen, Netherlands; Frankfurt, Germany; Chu de Reims, France; Horsham, United Kingdom; East Hanover, United States Of America; Basel, Switzerland)
| |
Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators
L. Fabbri, R. Rodriguez-Roisin, C. Orevillo, C. Fernandez, P. Darken, E. St. Rose, C. Kollar, C. Reisner (Modena, Italy; Barcelona, Spain; Redwood City, Little Falls, United States Of America)
| |
Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD
J. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, A. Church (Chapel Hill, Minneapolis, Research Triangle Park, United States Of America; Uxbridge, United Kingdom)
| |
Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials
F. Maltais, S. Singh, A. Donald, A. Church, G. Crater, A. Goh, J. Riley (Québec, Mississauga, Canada; Leicester, Uxbridge, United Kingdom; Research Triangle Park, United States Of America)
| |
FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
A. Agusti, M. Corradi, G. Cohuet, S. Vezzoli, D. Singh, J. Vestbo, P. Paggiaro, P. Jones, S. Petruzzelli, J. Wedzicha (Barcelona, Spain; Parma, Pisa, Italy; Manchester, London, United Kingdom)
| |
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
A. Koch, P. Paggiaro, A. Hamilton, L. Hart, L. Korducki, M. C. De Salvo, E. Pizzichini (Bochum, Germany; Pisa, Italy; Burlington, Canada; Ridgefield, United States Of America; Buenos Aires, Argentina; Santa Catarina, Brazil)
| |
Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies
A. Koch, E. Pizzichini, A. Hamilton, L. Hart, L. Korducki, M. C. De Salvo, P. Paggiaro (Bochum, Germany; Santa Catarina, Brazil; Burlington, Canada; Ridgefield, United States Of America; Buenos Aires, Argentina; Pisa, Italy)
| |
Population pharmacokinetics and pharmacodynamics of GSK961081 (MABA) in patients with moderate to severe COPD
C. Ambery, P. Wielders, A. Ludwig-Sengpiel, R. Chan, J. Riley (Uxbridge, United Kingdom; Eindhoven, Netherlands; Luebeck, Germany)
| |
Use of intravenous (IV) aminophylline in acute exacerbations of COPD with decompensated acidotic type 2 respiratory failure (T2RF) requiring non-invasive ventilation (NIV)
E. Benison, M. Murthy, R. Yadavilli, H. Burhan (Liverpool, United Kingdom)
| |
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study
D. Singh, H. Pujol, A. Ribera, B. Seoane, C. Astbury, S. Ruiz, G. de Miquel (Manchester, United Kingdom; Barcelona, Spain)
| |